

February, 09, 2017

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI - 400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI - 400 001 Company Code No. 524804
---	---

Dear Sir,

Sub: Change in the Board of Directors

We wish to inform you the following changes in the Board of Directors of the Company:

1. Dr. D. Rajagopala Reddy has submitted his resignation as Independent Director of the Company. The Board of Directors of the Company at its meeting held on 9th February, 2017 has noted and taken on record his resignation with effect from 10th February, 2017.
2. The Board of Directors of the Company at its meeting held on 9th February, 2017 has appointed Mr. Rangaswamy Rathakrishnan Iyer as an Additional Independent Director of the Company with effect from 9th February, 2017. Brief profile of Mr. Rangaswamy Rathakrishnan Iyer is given as an Annexure to this letter.

We request you to take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED


B.ADI REDDY
Company Secretary



Annexure

Mr. Rangaswamy Rathakrishnan Iyer is an Advisor / Consultant to various Multinational and Indian Pharma Companies in the areas of Business Strategy and Business Development. He has been the Industry Advisor to consulting firms and advised in the areas of Intellectual Property Rights/Regulatory matters and has also worked on advocacy with the Govt and the Indian Pharma Companies

Mr. Rangaswamy Iyer holds a Post Graduate degree in Commerce and MBA in Finance from Bombay University.

He has also been:

- President of Organisation of Pharmaceutical Producers of India (OPPI) from 2007 to 2009 and prior to that was Vice President for 4 years.
- President of American Chamber of Commerce, Mumbai Chapter.
- Managing Committee Member of Bombay Chamber of Commerce for 4 years and of Indian Merchants Chamber for one year.

He has worked on behalf of the Pharma Industry with the Govt. of India on matters relating to Drug Pricing Policy and the Intellectual Property Rights.

In recognition of his contribution to the industry, he was adjudged as the 33rd most influential person in the Global Pharmaceutical Industry by World Pharmaceutical Frontiers in 2009, a leading UK Pharma magazine.

